MassBio

The 2025 BIO International Convention is coming to Boston on June 16-19! Join us in the Massachusetts Pavilion for the industry’s largest gathering of the full biotech ecosystem from across the globe from the lab, clinical trials, manufacturing, business development, and marketing launch. The Massachusetts Pavilion will be buzzing with activity surrounding our engaging speaking program, interactive exhibit, and lively meeting spaces. Several tiers of sponsorship are available, contact Chief Business Officer Laura Hamilton. Learn more: https://lnkd.in/ecc3nimN

𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞: Kymera Therapeutics' Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs. Full video: https://lnkd.in/gs7Y6E92 BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics Inc.. She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data. Full video: https://lnkd.in/g7AJyCEK BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

Last night was our Patient Advocacy Roundtable - our first roundtable of the year! And what a great session with our featured speaker, Pfizer's Dr. Ann-Marie Richard, on "Incorporating Patient Advocacy into Drug Development from Start to Finish." MassBio's roundtables are groups of individuals with similar responsibilities and titles from life sciences MassBio member companies assembled to discuss best practices, exchange ideas, and collaborate in unique ways. Learn more and see our upcoming roundtables: https://lnkd.in/e6me4fhP #PatientDriven

“The bases are loaded and we are ready for some real home runs on both the discovery side and the clinical development side,” said Colin Hill, CEO of Aitia, at the State of Possible. “I think they are going to happen in Massachusetts.” Read more about AI, #techbio, and the future of life sciences innovation in Massachusetts in our latest blog post by guest contributor Myles Goldman: https://lnkd.in/eQFqCeUB. #PatientDriven #stateofpossible25 #thisistheplace

We're still glowing from last week's State of Possible Conference where our community gathered and showed what this industry is all about. View the photos and relive moments from the event: https://lnkd.in/eZbqgbn5 A special thank you to all of our sponsors for their continued support! Sustaining Sponsors Johnson & Johnson | Eli Lilly and Company | Massachusetts Life Sciences Center | Thermo Fisher Scientific | Vertex Pharmaceuticals Silver Sponsors Alexion Pharmaceuticals, Inc. | Ipsen | Sharp Sterile Manufacturing | Takeda Copper Sponsors Biodesix, Inc. | Boston Biodevelopment LLC | Evaluate Ltd | Mispro | Novartis | Servier Pharmaceuticals | Tobin Scientific | Veolia #StateofPossible25 #PatientDriven

𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech. He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing. Full video: https://lnkd.in/g2Z_Eg8d BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

Reconnect, collaborate, and innovate with over 2,800 leaders at #BioITExpo starting today until Friday, April 4 in Boston, to explore advancements in digital and data transformations; AI; generative AI; machine learning (AI); real-world data strategies, challenges, and solutions; pilot programs; new product results; and biotech investment trends. Uniting a community of experts in the #lifesciences, pharmaceuticals, clinical research, healthcare, informatics and technology, they push the boundaries of what’s possible in biomedical research, drug discovery and development, and patient outcomes. Register now: https://lnkd.in/eUXPHRsy

𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials. She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs. Full video: https://lnkd.in/gFapDPzH BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | Klein Hersh | Savills

A statement from MassBio CEO & President Kendalle Burlin O'Connell, Esq. on the staffing cuts at #HHS and #FDA.